Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

▤ Summary

Zymeworks shared new Phase 1 data for ZW191, its folate receptor alpha-targeting antibody-drug conjugate, at an oncology congress. The results show strong anti-tumor activity in platinum-resistant ovarian cancer and encouraging responses in endometrial cancer, including in FR-negative tumors. The company reported a manageable safety profile, early and durable responses, and a median progression-free survival of 7.6 months across cohorts. Dose-optimization enrollment is complete, and the next data readout is expected to help guide future development decisions.

▦ Linked Companies